Vedolizumab therapy for irritable bowel syndrome (WP5512)

Homo sapiens

Open in new tab Open in Newt (SBGN)
Download PNG Download SVG Download JSON Download GPML Learn more about Downloads
"Vedolizumab is a humanized monoclonal antibody with a predominantly gastrointestinal effect. It specifically inhibits leucocyte integrin α4β7, thus preventing its interaction with mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1), which is involved in the migration of lymphocytes from the blood stream to the intestinal tissue. Vedolizumab is indicated in the treatment of moderate to severe active Crohn's disease and ulcerative colitis in adult patients with poor response, loss of response, or intolerance to conventional treatment or to tumour necrosis factor alpha (TNF-α) antagonists." Inspired by Figure 1 in https://pubmed.ncbi.nlm.nih.gov/31470005/. Vedolizumab is also known by its trade name, Entyvio.

Authors

Eric Weitz

Activity

last edited

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Disease Ontology

Crohn's disease irritable bowel syndrome ulcerative colitis

Cell Type Ontology

endothelial cell of vascular tree lymphocyte

Participants
Query Drugst.One

Label Type Compact URI Comment
Vedolizumab Metabolite drugbank:DB09033
ITGA4 GeneProduct ensembl:ENSG00000115232
ITGB7 GeneProduct ensembl:ENSG00000139626
ITGB1 GeneProduct ensembl:ENSG00000150093
ITGA2 GeneProduct ensembl:ENSG00000164171
ITGB2 GeneProduct ensembl:ENSG00000160255
SELPLG GeneProduct ensembl:ENSG00000110876
SELE GeneProduct ensembl:ENSG00000007908
ICAM1 GeneProduct ensembl:ENSG00000090339
VCAM1 GeneProduct ensembl:ENSG00000162692
MADCAM1 GeneProduct ensembl:ENSG00000099866

References